益气补血养阴汤加减联合DP/C化疗方案在中晚期非小细胞肺癌中的应用效果观察  

Observation on the effect of modified Yiqi Buxue Yangyin Decoction combined with DP/C chemotherapy in advanced non-small cell lung cancer

作　　者：杨宇辉 YANG Yu-hui(Quanzhou Guangqian Hospital,Quanzhou 362321,China)

机构地区：[1]泉州市光前医院,362321

出　　处：《中国现代药物应用》2024年第9期130-133,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探究益气补血养阴汤加减联合DP/C化疗方案在中晚期非小细胞肺癌(NSCLC)中的应用效果。方法选取中晚期非小细胞肺癌患者94例,按照治疗方式不同分为对照组和观察组,各47例。对照组给予DP/C化疗方案治疗,观察组给予益气补血养阴汤加减联合DP/C化疗方案治疗。对比两组治疗效果、肿瘤相关标志物[糖类抗原19-9(CA19-9)、细胞角蛋白19片段抗原(CYFRA21-1)、癌胚抗原(CEA)]水平、中医证候积分、不良反应发生率。结果观察组疾病控制率(DCR)为74.47%,比对照组的53.19%高(χ^(2)=4.608,P=0.032<0.05)。观察组CA19-9、CYFRA21-1、CEA水平分别为(32.17±5.54)U/ml、(2.77±0.81)ng/ml、(8.05±0.88)μg/L,比对照组的(35.54±5.21)U/ml、(3.34±0.89)ng/ml、(9.12±0.97)μg/L低(P<0.05)。观察组咳嗽、痰血、神乏疲力、自汗盗汗积分分别为(1.23±0.25)、(1.68±0.32)、(1.32±0.37)、(1.51±0.35)分,比对照组的(2.12±0.36)、(2.34±0.54)、(1.98±0.49)、(1.89±0.42)分低(P<0.05)。观察组不良反应发生率6.38%比对照组的21.28%低(χ^(2)=4.374,P=0.036<0.05)。结论中晚期非小细胞肺癌患者,予以益气补血养阴汤加减联合DP/C化疗方案治疗,能改善肿瘤相关标志物的表达,改善患者中医证候积分,减少不良反应,进而提高治疗效果。Objective To explore the practical effect of modified Yiqi Buxue Yangyin Decoction combined with DP/C chemotherapy in advanced non-small cell lung cancer(NSCLC).Methods 94 patients with advanced non-small cell lung cancer were divided into a control group and an observation group according to different treatment methods,with 47 cases in each group.The control group was treated with DP/C chemotherapy,and the observation group was treated with modified Yiqi Buxue Yangyin Decoction and DP/C chemotherapy.The treatment effect,tumor-related markers[carbohydrate antigen 19-9(CA19-9),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA)]level,traditional Chinese medicine syndrome score,and the incidence of adverse reactions of the two groups were compared.Results The disease control rate(DCR)in the observation group was 74.47%,which was higher than 53.19%in the control group(χ^(2)=4.608,P=0.032<0.05).The levels of CA19-9,CYFRA21-1 and CEA in the observation group were(32.17±5.54)U/ml,(2.77±0.81)ng/ml and(8.05±0.88)μg/L,which were lower than(35.54±5.21)U/ml,(3.34±0.89)ng/ml and(9.12±0.97)μg/L in the control group(P<0.05).The scores of cough,bloody phlegm,fatigue and night sweat in the observation group were(1.23±0.25),(1.68±0.32),(1.32±0.37)and(1.51±0.35)points,which were lower than(2.12±0.36),(2.34±0.54),(1.98±0.49)and(1.89±0.42)points in the control group(P<0.05).The observation group had incidence of adverse reactions of 6.38%,which was lower than 21.28%in the control group(χ^(2)=4.374,P=0.036<0.05).Conclusion For patients with advanced non-small cell lung cancer,modified Yiqi Buxue Yangyin Decoction combined with DP/C chemotherapy can improve the expression of tumor-related markers,improve patients'traditional Chinese medicine syndrome score,reduce adverse reactions,and then improve the treatment effect.

关 键 词：中晚期 非小细胞肺癌 益气补血养阴汤加减 DP/C化疗方案 应用效果 

分 类 号：R734.2[医药卫生—肿瘤]